Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Atike Pınar ERDOĞAN"'
Autor:
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzaffer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment
Externí odkaz:
https://doaj.org/article/042edc2981bf4d52a01526b7a7c03f4f
Autor:
Hasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, Miraç Özen, Merve Keskinkılıç, Sercan Ön, Abdussamet Çelebi, Bengü Dursun, Ömer Acar, Seda Kahraman, Musa Barış Aykan, Ömür Kaman, Akif Doğan, Atike Pınar Erdoğan, Özde Melisa Celayir, Damla Günenç, Deniz Can Güven, İbrahim Vedat Bayoğlu, Tuğba Yavuzşen, İlhan Hacıbekiroğlu, Mevlüde İnanç, Saadettin Kılıçkap, Şuayib Yalçın, Sercan Aksoy
Publikováno v:
Breast, Vol 66, Iss , Pp 85-88 (2022)
Background: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), h
Externí odkaz:
https://doaj.org/article/18da86563ce64050a659105850fa47be
Publikováno v:
Middle East Current Psychiatry, Vol 29, Iss 1, Pp 1-8 (2022)
Abstract Background Cancer patients are in the high-risk group of getting COVID-19 infection and experiencing a severe course. Anxiety of cancer patients about how they pass this pandemic process and how changes in the health system would influence t
Externí odkaz:
https://doaj.org/article/c3ab78e956074561a34b9bd5ea8ea405
Autor:
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzafer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/62814a4471cb45089f6723c0cccc8157
Publikováno v:
Mediterranean Journal of Infection, Microbes and Antimicrobials, Vol 3 (2014)
Listeria monocytogenes are gram-positive bacilli causing epidemics through contagious food. It may lead to infections in the elderly and immunocompromised host. Although in vitro efficacy of levofloxacin is promising, published experience is limited.
Externí odkaz:
https://doaj.org/article/f54a2b1a270240d2b58a44e7d573ccab
Autor:
Ferhat EKİNCİ, Gonca Akdere ATEŞ, Atike Pınar ERDOĞAN, Cumali ÇELİK, Ahmet DİRİCAN, Gamze GÖKSEL
Publikováno v:
Bangladesh Journal of Medical Science. 22:68-76
Objective: The “centrality of events scale” (CES) was formed to determine to what extent this localisation of a traumatic memory is formed. The CES was used in this study to determine how overshadowed the cancer disease was by fear of COVID-19 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd9ca5ce033971f6cec68b4967e57d25
https://doi.org/10.3329/bjms.v22i1.61855
https://doi.org/10.3329/bjms.v22i1.61855
Publikováno v:
Journal of Infection and Chemotherapy. 28:1310-1316
To evaluate the factors affecting seropositivity and antibody levels after SARS-CoV-2 vaccines in patients with cancer because they were excluded from clinical studies of SARS-CoV-2 vaccines.This prospective, observational, single-center study includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f491215b40c80ee8bff60bf542e745e0
https://doi.org/10.1016/j.jiac.2022.05.021
https://doi.org/10.1016/j.jiac.2022.05.021
Autor:
Mustafa Gürbüz, Yasin Kutlu, Erman Akkuş, Elif Berna Köksoy, Naziyet Köse, Bala Başak Öven, Başak Oyan Uluç, Atike Gökçen Demiray, Dilek Erdem, Bilgin Demir, Nazım Serdar Turhal, Necdet Üskent, Sinem Akbaş, Fatih Selçukbiricik, Ali İnal, Ahmet Bilici, Ömer Fatih Ölmez, Devrim Çabuk, Çağlar Ünal, Mutlu Hızal, Mehmet Ali Nahit Şendur, Mustafa Korkmaz, Nuri Karadurmuş, İsmail Ertürk, Sema Sezgin Göksu, Ali Murat Tatlı, Deniz Can Güven, Saadettin Kılıçkap, Nail Paksoy, Adnan Aydıner, Havva Yeşil Çınkır, Özlem Özkul, Akın Öztürk, Sevinç Ballı, Yasemin Kemal, Atike Pınar Erdoğan, Özlem Er, Perran Fulden Yumuk, Ahmet Demirkazık
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:3547-3555
Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a345459815bcd72a8a16fb661d35462
https://doi.org/10.1007/s00432-022-04087-x
https://doi.org/10.1007/s00432-022-04087-x
Autor:
Atike Pınar Erdoğan, Ferhat EKİNCİ, Ahmet ÖZVEREN, Emine Bihter ENİSELER, Bilgin DEMİR, Mustafa ŞAHBAZLAR
Publikováno v:
European Journal of Therapeutics.
Objective: The use of neoadjuvant chemotherapy (NACT) in breast cancer is increasing. The management of locally advanced breast cancer differs due to the approach of the center to which the patient applied and the approach of the following physician.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5e7e841ae155063cd8329796ee64aa7
https://doi.org/10.58600/eurjther.20232902-347.y
https://doi.org/10.58600/eurjther.20232902-347.y
Autor:
Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukbiricik, Serkan Menekse, Eyyüp Cavdar, Akın Ozturk, Esma Türkmen Bekmez, Serdal Turhal, Sadettin Kilickap, Hasan Çağrı Yildirim, Başak Oyan, Asude Aksoy, Fatma Paksoy Turkoz, Engin Kut, Nuran Katgi, Teoman Sakalar, Murat Akyol, Halil İbrahim Ellez, Atakan Topcu, Atike Pınar Erdoğan, Kezban Nur Pilanci, Engin Hedem, Hacı Arak, Nadiye Akdeniz, Özkan Alan, Burcu Yapar, Deniz Nart, Perran Fulden Yumuk
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 149:865-875
Objectives: To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods: We retrospectively evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6dfec0cbcbdd9f35f252256f8357168
https://doi.org/10.1007/s00432-022-03984-5
https://doi.org/10.1007/s00432-022-03984-5